Unit | Clinical Operations
Over 20 Years' Experience as Clinical Trials Service Provider
Swiss TPH has extensive expertise in clinical trial service provision, with a successful track record of operating and facilitating research in resource-constraint settings for over 20 years. We understand the barriers to conducting clinical trials in difficult settings and offer strategic, customised solutions with a high level of flexibility. We appreciate the intricacies of strategic planning in these settings and aim to deliver the highest quality data for clinical trials tailored to each unique project.
We do this through:
- Local “know-how” of regional context
- Understanding the “patient pathway” in various settings
- Academic and scientific innovation
- Clinical expertise and management
We propose study designs and monitoring solutions to promote evidence-based practices that lead to meaningful, sustainable and effective outputs. By working with healthcare providers in an open, transparent manner, we enrich our local understanding and thus enhance the quality to deliver customer-focused clinical trials.
Head of Unit
+41612848966
elisabeth.reus@swisstph.ch
Our Business Modell
Our Philosophy
Access to effective, evidence-based medicine is a fundamental right, not a privilege.
Promoting evidence-based medicine and conducting clinical research requires customised and optimised solutions with a fully integrated, robust quality system at each level – starting at the earliest development stages through to final implementation. Provision of the highest quality and data integrity will allow the downstream use of collected data for the evaluation of drugs, diagnostics and vaccines, ultimately enabling FDA or EMA accreditation of successful candidates, support evidence-based medicine practices and contribute to national and international disease management guidelines. Our dedicated team is committed to these principles.
Our team
We are a global, experienced, multidisciplinary, multilingual team comprised of scientists, clinicians, and experienced medical and administrative staff. Through our combined clinical, research and local expertise with long-standing partnerships in an extensive global network of regional collaborators, we aim to deliver the highest-quality consumer-focused clinical trial results.
Project Highlights
ANTICOV
The ANTICOV study aims to identify one or two treatments that could be used to treat mild and moderate cases of COVID-19, to stop the disease from getting more serious. The goal of the study is to find a treatment to help avoid mass hospitalizations in African health systems with limited intensive care facilities. If successful, it will also have important implications for other regions. Read more about ANTICOV
Fexinidazole against African Human Trypanosomiasis
Human Africa Trypanosomiasis is a life-threatening neglected disease. To date nifurtimox-eflornithine combined therapy (NECT) is the Standard Treatment for late-stage HAT. Nevertheless, NECT is still far from ideal given the environment in which HAT patients live. There is an urgent need to develop less toxic and easier-to-use products. One promising agent is Fexinidazole. Read more about the project
Pediatric Praziquantel Formulation for Treating Schistosomiasis
Schistosomes, parasitic blood flukes, cause the chronic disaese schistosomiasis. Today, the gold standard of treatment is praziquantel which is only suitable for adults and school-aged children. Thus, a palliative, effective and safe praziquantel formulation to treat young children is absolutely required. To reach this aim, the Pediatric Praziquantel Consortium was founded in 2012. More information
Treatment of Multidrug-Resistant Tuberculosis
Tuberculosis is one of the most deadly infectious diseases in the world. Treatment is complex especially in case of multidrug-resistant tuberculosis. Particularly patients in low-resource countries often lack access or do not complete treatment regimen. TB PRACTECAL is a pioneering new clinical trial aiming to find a radically improved course of treatment for drug-resistant tuberculosis. Read more about the project
Eveline Ackermann
Fabio Bachmann
Sonja Bernhard
Valentina Butoescu
Julie Catusse
Suzanne Gajewski
Jarmila Hanekova
Eric Huber
Mischa Joubert
Morgane Nusbaumer
Elisabeth Reus
Fatma Toumi
Our Study Sites
Selected Projects
All ProjectsLatest Publications
All PublicationsKande Betu Ku Mesu V et al. Oral fexinidazole for stage 1 or early stage 2 African Trypanosoma brucei gambiense trypanosomiasis: a prospective, multicentre, open-label, cohort study. Lancet Glob Health. 2021;9(7):e999-e1008. DOI: 10.1016/s2214-109x(21)00208-4
Mahende M.K et al. Comparative palatability of orally disintegrating tablets (ODTs) of Praziquantel (L-PZQ and Rac-PZQ) versus current PZQ tablet in African children: A randomized, single-blind, crossover study. PLoS Negl Trop Dis. 2021;15(6):e0007370. DOI: 10.1371/journal.pntd.0007370
N'Goran E et al. Challenges and lessons from conducting a paediatric clinical trial in sub-Saharan Africa: the case of the praziquantel oral dispersible tablets phase II study in Côte d'Ivoire. Adv Parasitol. 2019;103:75-89. DOI: 10.1016/bs.apar.2018.09.002
Steiner-Monard V et al. The candidate blood-stage malaria vaccine P27A induces a robust humoral response in a fast track to the field phase I trial in exposed and non exposed volunteers. Clin Infect Dis. 2019;68(3):466-474. DOI: 10.1093/cid/ciy514
Mesu V.K.B.K et al. Oral fexinidazole for late-stage African Trypanosoma brucei gambiense trypanosomiasis: a pivotal multicentre, randomised, non-inferiority trial. Lancet. 2018;391(10116):144-154. DOI: 10.1016/S0140-6736(17)32758-7